Immuron secured exclusive U.S. distribution rights for PROIBS with Calmino group AB, targeting a digestive and gut health supplement market valued at $4.16 billion. The agreement expands Immuron’s digestive health portfolio and gives investors a defined U.S. commercial opportunity for a medical device already launched in Australia.
Key Highlights
- Immuron executed an exclusive U.S. distribution agreement for PROIBS with Calmino group AB.
- A usability study of 1,003 PROIBS users found the product helpful for 94% of participants.
- The company said 91% of users experienced an improvement in daily life, while 98% would recommend PROIBS to someone else.
Immuron Ltd (NASDAQ: IMRN) executed an exclusive U.S. distribution agreement for PROIBS with Calmino group AB, targeting a subset of the U.S. digestive and gut health supplement market, which is valued overall at $4.16 billion.
PROIBS Agreement Covers U.S. Distribution Immuron
executed the agreement with Calmino group AB on September 4, 2026. It contains AVH200®, a substance derived from Aloe barbadensis Mill. Whose gel-forming components support the intestinal mucosal barrier. The product is suitable for long-term use, and the company said it has an excellent safety profile with no known interactions with other medications. The device is European certified.
User Study Supports Digestive Health Positioning Calmino’s usability study covered 1,003 users.
PROIBS was considered helpful by 94% of participants, while 91% said it improved their daily life and 98% said they would recommend it to someone else. Immuron said the agreement forms part of a strategy to build a portfolio of innovative digestive health products in the United States. The company launched PROIBS in Australia during FY26 and described the U.S. agreement as an opportunity to extend that portfolio with a product it characterizes as science-driven and physician- and dietitian-recommended.
FAQs
Q: What did Immuron’s PROIBS U.S. distribution agreement change?
A: Immuron executed an exclusive U.S. distribution agreement for PROIBS with Calmino group AB on September 4, 2026. The agreement targets a subset of the U.S. digestive and gut health supplement market.
Q: What results did the PROIBS usability study show?
A: Calmino’s study involved 1,003 users. PROIBS was helpful for 94% of participants, 91% reported improved daily life, and 98% would recommend it.
Q: What market is Immuron targeting with PROIBS?
A: Immuron is targeting a subset of the U.S. digestive and gut health supplement market, which is valued overall at $4.16 billion.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.